EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prevalence of Metabolic-Dysfunction-Associated Steatotic Liver Disease in Patients with Psoriasis and Psoriatic Arthritis

Nuria Vegas-Revenga iD, Cristina San Juan López, Blanca Sampedro Andrada iD, Victoria Morillo Montañés, Irati Urionaguena-Onaindia, Nahia Plaza-Aulestia iD, Sandra Pérez Prado, Itziar Calvo Zorrilla iD, Oihane Ibarguengoitia-Barrena, David Montero Seisdedos, Libe Ibarrola-Paino, Lucía Vega-Álvarez und 2 weitere

Diagnostics · 22.07.2026 · 16 (14) · 2292

DOI: 10.3390/diagnostics16142292 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diagnostics, online erschienen am 22.07.2026. Verfasst von Nuria Vegas-Revenga und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Hospital Universitario Galdakao-Usansolo, 48960 Galdakao, Bizkaia, Spain. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Psoriatic disease (PsD) is a chronic cutaneous and systemic inflammatory condition associated with an increased risk of metabolic-dysfunction-associated steatotic liver disease (MASLD) and its complications. Our objective was to determine the prevalence of MASLD in our overall cohort and to analyze it across PsO, PsA, and healthy control groups. The secondary objective was to describe hepatic steatosis and fibrosis using transient elastography (FibroScan®) and to characterize hepatic scores within each study group. The third objective was to assess whether specific cardiovascular risk factors were associated with the development of hepatic steatosis or fibrosis in individuals with PsD and healthy controls.

Methods

A cross-sectional study was conducted at a single tertiary care center, enrolling consecutive patients from the Dermatology and Rheumatology Departments. Individuals with pre-existing liver disorders were excluded. The control cohort comprised 102 healthy volunteers without chronic inflammatory or hepatic conditions. All participants underwent comprehensive clinical assessments, serum biomarker analysis, and FibroScan®.

Results

A total of 330 participants were included, 228 with PsD (101 with psoriasis (PsO) and 127 with psoriatic arthritis (PsA)) and 102 healthy controls. MASLD was present in 39% of the overall cohort, with a prevalence of 47.5% in PsO, 32.2% in PsA, and 8.8% in healthy controls (p < 0.001). FibroScan® measurements indicated a tendency toward increased liver stiffness and higher controlled attenuation parameter (CAP) values in patients with PsD. Both PsO and PsA groups showed a higher prevalence of cardiometabolic risk factors compared with controls (p < 0.05). Non-invasive fibrosis indices were also significantly altered in both patient groups.

Conclusions

Patients with PsD demonstrated a higher prevalence of MASLD, hepatic fibrosis, and cardiometabolic abnormalities compared with healthy controls in our cohort.

Schlagwörter

Stichwörter der Autor:innen

disease-modifying antirheumatic drugsfibrosismetabolic syndromemetabolic-dysfunction-associated steatotic liver diseasepsoriatic diseasesteatosis

Autor:innen und Institutionen

  • Department of Rheumatology, Hospital Universitario Galdakao-Usansolo, 48960 Galdakao, Bizkaia, Spain.
  • Biobizkaia Health Research Institute, Osakidetza, Cruces, 48903 Barakaldo, Bizkaia, Spain.
  • Department of Medicine, Euskal Herriko Unibertsitatea, 48940 Leioa, Bizkaia, Spain.
  • Department of Gastroenterology and Hepatology, Hospital Universitario Galdakao-Usansolo, 48960 Galdakao, Bizkaia, Spain.
  • Centro Vasco de Aparato Digestivo, 48014 Bilbao, Bizkaia, Spain.
  • Department of Dermatology, Hospital Universitario Galdakao-Usansolo, 48960 Galdakao, Bizkaia, Spain.

ORCID-Profile: Nuria Vegas-Revenga, Blanca Sampedro Andrada, Nahia Plaza-Aulestia, Itziar Calvo Zorrilla, Aitor Orive Calzada

Zitieren

APA

Vegas-Revenga, N., San Juan López, C., Sampedro Andrada, B., Morillo Montañés, V., Urionaguena-Onaindia, I., Plaza-Aulestia, N., Pérez Prado, S., Calvo Zorrilla, I., Ibarguengoitia-Barrena, O., Montero Seisdedos, D., Ibarrola-Paino, L., Vega-Álvarez, L., Orive Calzada, A., & Garcia Llorente, J. F. (2026). Prevalence of Metabolic-Dysfunction-Associated Steatotic Liver Disease in Patients with Psoriasis and Psoriatic Arthritis. Diagnostics, 16(14), 2292. https://doi.org/10.3390/diagnostics16142292

Vancouver

Vegas-Revenga N, San Juan López C, Sampedro Andrada B, Morillo Montañés V, Urionaguena-Onaindia I, Plaza-Aulestia N, et al. Prevalence of Metabolic-Dysfunction-Associated Steatotic Liver Disease in Patients with Psoriasis and Psoriatic Arthritis. Diagnostics. 2026;16(14):2292. doi:10.3390/diagnostics16142292

BibTeX
@article{VegasRevenga2026,
  author = {Vegas-Revenga, Nuria and San Juan López, Cristina and Sampedro Andrada, Blanca and Morillo Montañés, Victoria and Urionaguena-Onaindia, Irati and Plaza-Aulestia, Nahia and Pérez Prado, Sandra and Calvo Zorrilla, Itziar and Ibarguengoitia-Barrena, Oihane and Montero Seisdedos, David and Ibarrola-Paino, Libe and Vega-Álvarez, Lucía and Orive Calzada, Aitor and Garcia Llorente, José Francisco},
  title = {Prevalence of Metabolic-Dysfunction-Associated Steatotic Liver Disease in Patients with Psoriasis and Psoriatic Arthritis},
  journal = {Diagnostics},
  year = {2026},
  volume = {16},
  number = {14},
  pages = {2292},
  doi = {10.3390/diagnostics16142292}
}
Kostenlos starten →